ATE366117T1 - Membranvesikel (omv) mit verbesserten eigenschaften - Google Patents

Membranvesikel (omv) mit verbesserten eigenschaften

Info

Publication number
ATE366117T1
ATE366117T1 AT03791150T AT03791150T ATE366117T1 AT E366117 T1 ATE366117 T1 AT E366117T1 AT 03791150 T AT03791150 T AT 03791150T AT 03791150 T AT03791150 T AT 03791150T AT E366117 T1 ATE366117 T1 AT E366117T1
Authority
AT
Austria
Prior art keywords
pellet
membrane vesicles
collecting
detergent
outer membrane
Prior art date
Application number
AT03791150T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Davide Serruto
Rini Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366117(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE366117T1 publication Critical patent/ATE366117T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
AT03791150T 2002-08-30 2003-09-01 Membranvesikel (omv) mit verbesserten eigenschaften ATE366117T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220194.5A GB0220194D0 (en) 2002-08-30 2002-08-30 Improved vesicles

Publications (1)

Publication Number Publication Date
ATE366117T1 true ATE366117T1 (de) 2007-07-15

Family

ID=9943238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791150T ATE366117T1 (de) 2002-08-30 2003-09-01 Membranvesikel (omv) mit verbesserten eigenschaften

Country Status (21)

Country Link
US (2) US20060166344A1 (de)
EP (5) EP2258388B1 (de)
JP (3) JP2006503822A (de)
CN (2) CN1688334A (de)
AT (1) ATE366117T1 (de)
AU (1) AU2003263534B2 (de)
BR (1) BRPI0314094A8 (de)
CA (1) CA2497165C (de)
CY (3) CY1107737T1 (de)
DE (1) DE60314756T2 (de)
DK (3) DK1534326T3 (de)
ES (4) ES2289351T3 (de)
FR (1) FR13C0046I2 (de)
GB (1) GB0220194D0 (de)
LU (1) LU92239I2 (de)
MX (1) MXPA05002316A (de)
NZ (1) NZ538673A (de)
PT (3) PT1534326E (de)
RU (1) RU2325184C2 (de)
SI (2) SI2258389T1 (de)
WO (1) WO2004019977A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9906927A (pt) * 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
AU761495B2 (en) 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23377A1 (es) * 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
CA2576280A1 (en) 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
DK1858919T3 (da) * 2005-02-18 2012-07-16 Novartis Vaccines & Diagnostic Immunogener fra uropathogen Escherichia coli
US20090074712A1 (en) * 2005-05-19 2009-03-19 Compton Methods for Treatment and Prevention of Infection
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (de) 2008-12-17 2011-09-28 Novartis AG Meningokokken-impfstoffe mit hämoglobin-rezeptor
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010242905B2 (en) * 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
US20110045528A1 (en) * 2009-08-20 2011-02-24 Srisuda Dhamwichukorn Apparatus and method for enhanced disruption and extraction of intracellular materials from microbial cells
EP2470205A1 (de) 2009-08-27 2012-07-04 Novartis AG Hilfsstoff mit aluminium, oligonukleotid und polykation
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
CN102480932B (zh) * 2009-09-01 2015-01-14 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2483390A2 (de) 2009-09-30 2012-08-08 Novartis AG Expression von meningokokken-fhbp-polypeptiden
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP5635690B2 (ja) 2010-07-01 2014-12-03 ポステック アカデミー‐インダストリー ファウンデーション 細菌由来マイクロベシクルを用いた癌治療及び癌診断方法
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
JP6002763B2 (ja) * 2011-07-07 2016-10-05 デ スタート デル ネダーランデン、フェルト．ドール デ ミニスター ファン フェーウェーエス グラム陰性細菌の外膜小胞を、洗浄剤を含まずに生産するためのプロセス
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
EP2823312B1 (de) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro-wirksamkeits basierte assay für protein-basierten meningokokken-impfstoffe
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
EP2861247B1 (de) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Impfstoffe gegen serogruppe-x-meningokokken
EP2877492A1 (de) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 als rezeptor für pilusvermittelte adhäsion von meningokokken an gefässendothelzellen
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
EP3400960A1 (de) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Aussenmembranvesikel
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3298031B1 (de) 2015-05-18 2020-10-21 BiOMVis Srl Immunogene zusammensetzungen enthaltend bakterielle aussenmembranvesikel und ihre verwendung
AU2016354444B2 (en) * 2015-11-10 2021-04-01 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
JP7105768B2 (ja) 2016-10-28 2022-07-25 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 細菌を保存するための方法および組成物
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
BR112019019440A2 (pt) * 2017-03-31 2020-04-14 Indian Council Medical Res vacina contra febre tifoide a base de vesículas de membrana externa de duas cepas diferentes de espécies de salmonella tifoide
JP7369690B2 (ja) 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞
US10793865B2 (en) 2018-06-05 2020-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions
EP3607967A1 (de) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modifizierte meningokokken fhbp polypeptide
KR102852282B1 (ko) 2018-11-06 2025-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
TW202045192A (zh) * 2019-02-22 2020-12-16 美商艾弗洛生物科技股份有限公司 細菌膜製劑
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP3799884A1 (de) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
JP2023541876A (ja) 2020-09-11 2023-10-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5993826A (en) 1993-03-02 1999-11-30 Board Of Regents, The University Of Texas Methods and compositions relating to useful antigens of moraxella catarrhalis
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
EP0671948B1 (de) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Adjuvantien enthaltende impfstoffzusammensetzung
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0710118T3 (da) * 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
EP0769019A1 (de) 1994-07-01 1997-04-23 Rican Limited Helicobacter pylori antigenische protein-praeparate und immunoassays
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0841944A2 (de) 1995-08-04 1998-05-20 University Of Guelph Neue impfstoffe und pharmazeutische zusammensetzungen enthaltend membranvesikeln aus mikroorganismen und verfahren zur herstellung derselben
EP0909323B1 (de) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bakterioferritin aus helicobacter pylori
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP5037747B2 (ja) 1997-01-30 2012-10-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用
EP1039935A4 (de) 1997-02-28 2005-04-27 Univ Iowa Res Found VERWENDUNG VON NUCLEINSÄUREN ENTHALTEND NICHT-METHYLIERTEN CpG-DINUKLEOTIDEN IN DER BEHANDLUNG VON LIPOPOLYSACCHARID-ASSOZIERTEN ERKRANKUNGEN
EP2172216A3 (de) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Verwendung von Nukleinsäuren, die unmethylierte CPG-Dinukleotide enthalten als Adjuvantien
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (de) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitoren von immunstimulatorischen DNA Sequenz Aktivität
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6451317B1 (en) * 1997-07-17 2002-09-17 Baxter International Inc. Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide
CA2300854C (en) 1997-08-21 2011-04-05 Peter Andre Van Der Ley Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
AU762606B2 (en) 1997-11-21 2003-06-26 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
ES2298128T3 (es) 1999-02-22 2008-05-16 Health Protection Agency Composiciones de vacuna neisseriana y metodos.
AU4673099A (en) 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
AUPQ005499A0 (en) * 1999-04-30 1999-05-27 Townsend, Roy Leslie Printing process
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
EP1221971A2 (de) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Verwendung der kombination von polyoxyethylen sorbitan ester und octoxynol als adjuvans und seine verwendung in impfstoffen
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0007433D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Recombinant transferrin binding proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6753015B2 (en) 2000-09-28 2004-06-22 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
AU2003260357B2 (en) * 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis

Also Published As

Publication number Publication date
ES2483592T3 (es) 2014-08-06
BR0314094A (pt) 2005-11-16
EP1534326B1 (de) 2007-07-04
PT1534326E (pt) 2007-10-17
AU2003263534B2 (en) 2010-08-05
JP2006503822A (ja) 2006-02-02
DE60314756T2 (de) 2008-03-06
US20150258188A1 (en) 2015-09-17
RU2005108994A (ru) 2006-02-10
CA2497165A1 (en) 2004-03-11
WO2004019977A2 (en) 2004-03-11
CN102188700A (zh) 2011-09-21
EP1864679B1 (de) 2014-06-18
CY1115777T1 (el) 2017-01-25
DK2258389T3 (da) 2013-08-26
CN1688334A (zh) 2005-10-26
CA2497165C (en) 2015-10-20
EP2258389B1 (de) 2013-06-05
BRPI0314094A8 (pt) 2018-04-03
GB0220194D0 (en) 2002-10-09
DE60314756D1 (de) 2007-08-16
PT2258389E (pt) 2013-08-22
NZ538673A (en) 2008-04-30
EP2258388B1 (de) 2014-08-13
DK1864679T3 (da) 2014-08-25
ES2423019T3 (es) 2013-09-17
CY1114570T1 (el) 2017-01-25
EP2258388A1 (de) 2010-12-08
EP1864679A2 (de) 2007-12-12
DK1534326T3 (da) 2007-10-22
JP2010150287A (ja) 2010-07-08
EP1534326A2 (de) 2005-06-01
JP2013139471A (ja) 2013-07-18
FR13C0046I2 (fr) 2014-05-16
CY1107737T1 (el) 2013-04-18
EP1864679A3 (de) 2008-04-02
FR13C0046I1 (de) 2013-09-06
RU2325184C2 (ru) 2008-05-27
ES2289351T3 (es) 2008-02-01
SI1864679T1 (sl) 2014-10-30
ES2520392T3 (es) 2014-11-11
EP2258390A1 (de) 2010-12-08
WO2004019977A3 (en) 2004-07-15
JP5808358B2 (ja) 2015-11-10
US20060166344A1 (en) 2006-07-27
MXPA05002316A (es) 2005-06-08
LU92239I2 (fr) 2013-09-04
PT1864679E (pt) 2014-09-25
EP2258389A1 (de) 2010-12-08
AU2003263534A1 (en) 2004-03-19
SI2258389T1 (sl) 2013-07-31

Similar Documents

Publication Publication Date Title
ATE366117T1 (de) Membranvesikel (omv) mit verbesserten eigenschaften
JP2006503822A5 (de)
ATE304369T1 (de) Intakte oder zerstörte insektenzellen als antigenadjuvant
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
WO2007076520A3 (en) Multivalent pcv2 immunogenic compositions and methods of producing such compositions
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
DE60236596D1 (de) Antikörper gegen das meningokokken adhäsin app
WO2000067774A3 (en) Materials for soft tissue augmentation and methods of making and using same
AU1463097A (en) Helicobacter pylori bacterioferritin
CN104073537A (zh) 一种利用复合蛋白酶制备活性胶原蛋白的方法
WO2004060303A3 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
CA2386126A1 (en) Method of improving gene transfer efficiency into plant cells
ATE447968T1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
SI1127943T1 (sl) Sredstva in postopki za ekspresijo homolognih in heterolognih proteinov v sevih Rhodococcus
DE60316258D1 (de) Verfahren zur herstellung von cs6-antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli-infektionen
ATE496745T1 (de) Holzbehandlungsmethode
RU2002132049A (ru) Способ получения липополисахаридов
CN102041253A (zh) 一种蛇毒蛋白的提取工艺
WO2002066053A3 (en) Method of treating or preventing disease characterized by cryptococcus neoformans infection
Nagel Extraction and Fractionation of B. pertussis Antigens In Order To Reduce The Reactogenic Properties of Pertussis Vaccines J. Nagel and S. de Graaf
ES8605576A1 (es) Un procedimiento para preparar una composicion contra infecciones virales de hepatitis b
RU99102863A (ru) Способ повышения эксплуатационных свойств абразивного инструмента
CN1710072A (zh) 分泌人白介素－2的重组卡介苗及其构建方法